Evaluating antitumor activity of Escherichia coli purine nucleoside phosphorylase against head and neck patient‐derived xenografts

Background Purine nucleoside phosphorylase (PNP) gene transfer represents a promising approach to treatment of head and neck malignancies. We tested recombinant adenovirus already in phase I/II clinical testing and leading‐edge patient‐derived xenografts (PDX) as a means to optimize this therapeutic...

Full description

Saved in:
Bibliographic Details
Published inCancer reports Vol. 6; no. 2; pp. e1708 - n/a
Main Authors Rab, Regina, Ehrhardt, Annette, Achyut, Bhagelu R., Joshi, Disha, Gilbert‐Ross, Melissa, Huang, Chunzi, Floyd, Katharine, Borovjagin, Anton V., Parker, William B., Sorscher, Eric J., Hong, Jeong S.
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.02.2023
John Wiley and Sons Inc
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Purine nucleoside phosphorylase (PNP) gene transfer represents a promising approach to treatment of head and neck malignancies. We tested recombinant adenovirus already in phase I/II clinical testing and leading‐edge patient‐derived xenografts (PDX) as a means to optimize this therapeutic strategy. Methods Our experiments investigated purine base cytotoxicity, PNP enzyme activity following treatment of malignant tissue, tumor mass regression, viral receptor studies, and transduction by tropism‐modified adenovirus. Results Replication deficient vector efficiently transduced PDX cells and mediated significant anticancer effect following treatment with fludarabine phosphate in vivo. Either 6‐methylpurine or 2‐fluoroadenine (toxic molecules generated by the PNP approach) ablated head and neck cancer cell proliferation. High levels of adenovirus‐3 specific receptors were detected in human tumor models, and vector was evaluated that utilizes this pathway. Conclusions Our studies provide the scientific foundation necessary to improve PNP prodrug cleavage and advance a new treatment for head and neck cancer.
Bibliography:Funding information
Eric J. Sorscher and Jeong S. Hong are co‐senior authors.
Emory University Winship Cancer Institute, Grant/Award Number: Cancer Animal Models shared resource; National Cancer Institute, Grant/Award Number: P30CA138292; National Institutes of Health, Grant/Award Number: R01DE026941; Northwestern University; Moscow State Medical University; Frederick National Laboratory for Cancer Research; Winship Cancer Institute of Emory University
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Funding information Emory University Winship Cancer Institute, Grant/Award Number: Cancer Animal Models shared resource; National Cancer Institute, Grant/Award Number: P30CA138292; National Institutes of Health, Grant/Award Number: R01DE026941; Northwestern University; Moscow State Medical University; Frederick National Laboratory for Cancer Research; Winship Cancer Institute of Emory University
ISSN:2573-8348
2573-8348
DOI:10.1002/cnr2.1708